Cardiovascular effect of incretin-based therapy in patients with type 2 diabetes mellitus: Systematic review and meta-Analysis

Je Yon Kim, Seungwon Yang, Jangik I. Lee, Min Jung Chang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: To assess the cardiovascular (CV) risk associated with the use of incretin-based therapy in adult patients with type 2 diabetes mellitus (T2DM) primary prevention group with low CV risks. Methods: The clinical studies on incretin-based therapy published in medical journals until August 2014 were comprehensively searched using MEDLINE, EMBASE and CENTRAL with no language restriction. The studies were systemically reviewed and evaluated for CV risks using a metaanalysis approach and where they meet the following criteria: clinical trial, incidence of predefined CV disease, T2DM with no comorbidities, age > 18 years old, duration of at least 12 weeks, incretin-based therapy compared with other antihyperglycaemic agents or placebo. Statistical analyses were performed using a Mantel-Haenszel (M-H) test. The odds ratios (OR) and their 95% confidence interval (CI) were estimated and displayed for comparison. Results: A total of 75 studies comprising 45,648 patients with T2DM were selected. The pooled estimate demonstrated no significance in decreased CV risk with incretin-based therapy versus control (M-H OR, 0.90; 95% CI, 0.81-1.00). Conclusions: This meta-analysis suggests that incretin-based therapy show no significant protective effect on CV events in T2DM primary prevention group with low CV risks. Prospective randomized controlled trials are required to confirm the results of this analysis.

Original languageEnglish
Article numbere0153502
JournalPloS one
Volume11
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

secretin
Incretins
systematic review
Medical problems
noninsulin-dependent diabetes mellitus
meta-analysis
Type 2 Diabetes Mellitus
Meta-Analysis
therapeutics
Primary Prevention
odds ratio
confidence interval
clinical trials
Odds Ratio
Confidence Intervals
hypoglycemic agents
Therapeutics
Hypoglycemic Agents
MEDLINE
cardiovascular diseases

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

@article{d3b3993a0b6142b9b2253f0ca688a729,
title = "Cardiovascular effect of incretin-based therapy in patients with type 2 diabetes mellitus: Systematic review and meta-Analysis",
abstract = "Background: To assess the cardiovascular (CV) risk associated with the use of incretin-based therapy in adult patients with type 2 diabetes mellitus (T2DM) primary prevention group with low CV risks. Methods: The clinical studies on incretin-based therapy published in medical journals until August 2014 were comprehensively searched using MEDLINE, EMBASE and CENTRAL with no language restriction. The studies were systemically reviewed and evaluated for CV risks using a metaanalysis approach and where they meet the following criteria: clinical trial, incidence of predefined CV disease, T2DM with no comorbidities, age > 18 years old, duration of at least 12 weeks, incretin-based therapy compared with other antihyperglycaemic agents or placebo. Statistical analyses were performed using a Mantel-Haenszel (M-H) test. The odds ratios (OR) and their 95{\%} confidence interval (CI) were estimated and displayed for comparison. Results: A total of 75 studies comprising 45,648 patients with T2DM were selected. The pooled estimate demonstrated no significance in decreased CV risk with incretin-based therapy versus control (M-H OR, 0.90; 95{\%} CI, 0.81-1.00). Conclusions: This meta-analysis suggests that incretin-based therapy show no significant protective effect on CV events in T2DM primary prevention group with low CV risks. Prospective randomized controlled trials are required to confirm the results of this analysis.",
author = "Kim, {Je Yon} and Seungwon Yang and Lee, {Jangik I.} and Chang, {Min Jung}",
year = "2016",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0153502",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

Cardiovascular effect of incretin-based therapy in patients with type 2 diabetes mellitus : Systematic review and meta-Analysis. / Kim, Je Yon; Yang, Seungwon; Lee, Jangik I.; Chang, Min Jung.

In: PloS one, Vol. 11, No. 4, e0153502, 01.04.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cardiovascular effect of incretin-based therapy in patients with type 2 diabetes mellitus

T2 - Systematic review and meta-Analysis

AU - Kim, Je Yon

AU - Yang, Seungwon

AU - Lee, Jangik I.

AU - Chang, Min Jung

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background: To assess the cardiovascular (CV) risk associated with the use of incretin-based therapy in adult patients with type 2 diabetes mellitus (T2DM) primary prevention group with low CV risks. Methods: The clinical studies on incretin-based therapy published in medical journals until August 2014 were comprehensively searched using MEDLINE, EMBASE and CENTRAL with no language restriction. The studies were systemically reviewed and evaluated for CV risks using a metaanalysis approach and where they meet the following criteria: clinical trial, incidence of predefined CV disease, T2DM with no comorbidities, age > 18 years old, duration of at least 12 weeks, incretin-based therapy compared with other antihyperglycaemic agents or placebo. Statistical analyses were performed using a Mantel-Haenszel (M-H) test. The odds ratios (OR) and their 95% confidence interval (CI) were estimated and displayed for comparison. Results: A total of 75 studies comprising 45,648 patients with T2DM were selected. The pooled estimate demonstrated no significance in decreased CV risk with incretin-based therapy versus control (M-H OR, 0.90; 95% CI, 0.81-1.00). Conclusions: This meta-analysis suggests that incretin-based therapy show no significant protective effect on CV events in T2DM primary prevention group with low CV risks. Prospective randomized controlled trials are required to confirm the results of this analysis.

AB - Background: To assess the cardiovascular (CV) risk associated with the use of incretin-based therapy in adult patients with type 2 diabetes mellitus (T2DM) primary prevention group with low CV risks. Methods: The clinical studies on incretin-based therapy published in medical journals until August 2014 were comprehensively searched using MEDLINE, EMBASE and CENTRAL with no language restriction. The studies were systemically reviewed and evaluated for CV risks using a metaanalysis approach and where they meet the following criteria: clinical trial, incidence of predefined CV disease, T2DM with no comorbidities, age > 18 years old, duration of at least 12 weeks, incretin-based therapy compared with other antihyperglycaemic agents or placebo. Statistical analyses were performed using a Mantel-Haenszel (M-H) test. The odds ratios (OR) and their 95% confidence interval (CI) were estimated and displayed for comparison. Results: A total of 75 studies comprising 45,648 patients with T2DM were selected. The pooled estimate demonstrated no significance in decreased CV risk with incretin-based therapy versus control (M-H OR, 0.90; 95% CI, 0.81-1.00). Conclusions: This meta-analysis suggests that incretin-based therapy show no significant protective effect on CV events in T2DM primary prevention group with low CV risks. Prospective randomized controlled trials are required to confirm the results of this analysis.

UR - http://www.scopus.com/inward/record.url?scp=84964349577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964349577&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0153502

DO - 10.1371/journal.pone.0153502

M3 - Article

C2 - 27078018

AN - SCOPUS:84964349577

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0153502

ER -